David R. Bauer
Lawyers
![](/sites/default/files/styles/teaser_headshot/public/lawyer-images/25898_drbauer.jpg?itok=Y1b0J_im)
Filters
Revolution Medicines $250 million at-the-market offering
The shares are listed on the Nasdaq Global Select Market
Affimed $100 million at-the-market offering
The shares are listed on the Nasdaq Global Market
Aligos Therapeutics $75 million at-the-market offering
The company issued common stock in the SEC-registered at-the-market offering
Inventiva at-the-market offering
We advised the sales agent on the SEC-registered offering of ADSs
Eli Lilly €1.8 billion and £250 million notes offering
The investment-grade offering included the company’s inaugural sustainability bonds
Maravai LifeSciences $1 billion secondary offering
The shares are listed on the Nasdaq Global Select Market
TBCASoft $25 million Series B equity funding round
We advised Naver Financial on its strategic investment in TBCASoft
Adagio Therapeutics $356 million IPO
We advised the underwriters on the IPO and Nasdaq listing
Nurix Therapeutics $150 million at-the-market offering
We advised the sales agent on the stock offering
RxSight $117.6 million IPO
We advised the underwriters in connection with the IPO and Nasdaq listing